A 3-Year Naturalistic Study of 53 Preschool Children With Pervasive Developmental Disorders Treated With Risperidone
The DOI matches its Crossref record.
Abstract
BACKGROUND: Only sparse and short-term data are available on pharmacologic treatments in very young children with pervasive developmental disorders (PDD). The purpose of this 3-year naturalistic study (March 1999-April 2002) is to describe the clinical outcome of a consecutive sample of preschool children with PDD treated with risperidone monotherapy. METHOD: The sample consisted of 45 boys and 8 girls aged 3.6 to 6.6 years (mean +/- SD age = 4.6 +/- 0.7 years) with a DSM-IV diagnosis of autistic disorder or PDD, not otherwise specified. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Clinical Global Impressions-Improvement scale (CGI-I), Children's Global Assessment Scale (CGAS), and a checklist for risperidone side effects. RESULTS: Patients received risperidone for a period ranging from 1 to 32 months (7.9 +/- 6.8 months). Twenty-five patients (47.2%) continued to receive risperidone after the study was completed, while 28 (52.8%) discontinued due to side effects (22.6% [N = 12]), parents' choice (18.9% [N = 10]), lack of efficacy (5.7% [N = 3]), and decision of the treating psychiatrist (5.7% [N = 3]). The optimal dose was 0.55 +/- 0.2 mg/ day. Significant improvement at the last observation was found in CPRS (p < .0001) and CGAS (p < .0001) scores. On the basis of both an improvement of 25% in CPRS score and a score of 1 or 2 on the CGI-I, 46.8% (N = 22) of subjects were considered responders. Behavioral disorders and affect dysregulation were more sensitive to treatment than was interpersonal functioning. Responders received higher doses of medication for a longer period and had a greater weight gain than did nonresponders. Increased prolactin levels without clinical signs (65% [24 of 37]) and increased appetite (15% [8 of 531) were the most frequent side effects. CONCLUSION: These findings suggest that low-dose risperidone may positively affect the clinical outcome in young children with PDD not only in the short-term, but also in the long-term period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
CORRELL, C. U., & CARLSON, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 403
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.09.003 · Cited by 215
Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”
Corcoran, C., Malaspina, D., & Hercher, L. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.021 · Cited by 183
KRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150
“Other than studies in subjects with pervasive developmental disorder (Masi et al., 2003; Zuddas et al., 2000), little has been done to examine the use of psychotropic medications of any kind Accepted January 4, 2006.”
BackgroundPandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0234-7 · Cited by 144
Tracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Canitano, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1450 · Cited by 74
Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study
Marrus, N., Underwood-Riordan, H., Randall, F., Zhang, Y., & Constantino, J. N. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0055 · Cited by 29
“Open label trials (Zuddas et al. 2000; Williams et al. 2006; Gencer et al. 2008) and naturalistic studies (Masi et al. 2003; Capone et al., 2008) also support risperidone’s ability to improve social functioning and autistic severity, and one controlled blinded study suggested that this effect was…”
Metadata
- Authors
- Masi, G., Cosenza, A., Mucci, M., & Brovedani, P.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-09-15
- Volume
- 64
- Issue
- 9
- Pages
- 1039-1047
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1966623168
- Cited by
- 101
- References
- 0
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.